Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Brain cancer; cancer

Isocitrate dehydrogenase 1 (IDH1)

Studies in patient samples and mice suggest a peptide derived from IDH1 containing the R132H mutation could be used as a vaccine to treat IDH1-mutant tumors. In humanized mice bearing IDH1 R132H tumors, vaccination with a 20-mer peptide of IDH1 R132H led to CD4+ T cell and antibody responses that decreased tumor growth compared with vehicle. A T cell response screen of peripheral blood mononuclear cells identified a subset of patients with IDH1 R132H gliomas who had T cells specific for the mutant dehydrogenase. Next steps include planning a Phase I trial of the peptide in patients with glioma to evaluate safety and immunogenicity.
At least 12 companies have vaccines for brain cancer in Phase III or earlier development (see Neo enough in glioma?, page 9).

SciBX 7(29); doi:10.1038/scibx.2014.855
Published online July 31, 2014

Patented; licensing status undisclosed

Schumacher, T. et al. Nature; published online June 25, 2014;
doi:10.1038/nature13387
Contact: Michael Platten, German Cancer Research Center, Heidelberg, Germany
e-mail:
m.platten@dkfz.de